BeyondSpring Says Data Demonstrate Potential of Plinabulin as Cancer Care Drug

BeyondSpring (BYSI) said pre-market Thursday that its lead asset, Plinabulin, a novel, non-G-CSF small molecule in development for the prevention of chemotherapy-induced neutropenia (CIN) and for the treatment of non-small cell lung cancer (NSCLC), mitigated both docetaxel CIN and thrombocytopenia in patients with advanced NSCLC in its phase 2 trial.

The biopharmaceutical company said that the data demonstrate Plinabulins’ potential as a cancer supportive care drug in preventing CIN and as an anti-cancer agent.

“We believe Plinabulin’s unique mechanism of action and therapeutic profile provide compelling evidence for its utility in a range of oncology indications, both as a standalone therapy and with potential to augment immunological effects as a combination with existing immuno-oncology agents,” commented BeyondSpring Chief Medical Officer Dr. Ramon Mohanlal.

The company said that it will present the data during the 19th World Conference on Lung Cancer of the International Association for the Study of Lung Cancer.